The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.

Saved in:

Bibliographic Details
Title:	The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.
Authors:	Goldstein, D¹, Spry, N², Cummins, M M³, Brown, C³, van Hazel, G A², Carroll, S⁴, Selva-Nayagam, S⁵, Borg, M⁵, Ackland, S P⁶, Wratten, C⁶, Shapiro, J⁷, Porter, I W T⁸, Hruby, G⁹, Horvath, L⁹, Bydder, S¹⁰, Underhill, C¹¹, Harvey, J¹², Gebski, V J³
Source:	British Journal of Cancer. 1/3/2012, Vol. 106 Issue 1, p61-69. 9p. 1 Diagram, 5 Charts, 3 Graphs.
Database:	Academic Search Ultimate

Description
ISSN:	00070920
DOI:	10.1038/bjc.2011.526